首页> 外文OA文献 >P309 Are results from VARSITY applicable to real world? Adalimumab versus vedolizumab as first line biological in moderate-to-severe IBD

【2h】

P309 Are results from VARSITY applicable to real world? Adalimumab versus vedolizumab as first line biological in moderate-to-severe IBD

机译：P309是来自适用于现实世界的校有度的结果吗？ Adalimumab与vedolizumab为第一线生物学在中度至严重的IBD中

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
A Moens; B Verstockt; D Alsoud; J Sabino; M Ferrante; S Vermeire;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. VARSITY: a Double-Blind, Double-Dummy, Randomised, Controlled Trial of Vedolizumab Versus Adalimumab in Patients with Active Ulcerative Colitis Schreiber S, Peyrin-Biroulet L, Loftus Jr EV, et al (2019) ECCO, OP 34 [J] . X. Treton Colon & Rectum . 2019,第3期

机译：virsity：Vedolizumab的双盲，双伪，随机对照试验，患有活性溃疡性结肠炎雪雷氏症患者，佩德林 - Biroulet L，Loftus JR Ev，等人（2019）ecco，OP 34
2. Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis [J] . Lauren Yokomizo, Berkeley Limketkai, K T Park BMJ Open Gastroenterology . 2016,第1期

机译：阿达木单抗，英夫利昔单抗或维多珠单抗作为中重度溃疡性结肠炎的一线生物疗法的成本效益
3. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis REPLY [J] . Sands Bruce E., Schreiber Stefan, Lirio Richard A. The New England journal of medicine . 2020,第1期

机译：Vedolizumab与Adalimumab用于中度至重度溃疡性结肠炎答复
4. Regulation of Novel biomedical Technologies: 1. On Presidents, Agencies and the Stem Cells Between Them: A Legal Analysis of President Bush's and the Federal Government's Policy on the Funding of Research Involving Human Embryonic Stem Cells 2. The Regulation of the Genetic Aspects of Donated Reproductive Tissue: The Need for Federal Regulation 3. Patents Versus Statutory Exclusivities in Biological Pharmaceuticals---Do We Really Need Both? [D] . Heled, Yaniv. 2011

机译：新型生物医学技术的法规：1.关于总统，机构及其之间的干细胞：对布什总统和联邦政府关于人类胚胎干细胞研究资助政策的法律分析2.捐赠的遗传方面的法规生殖组织：联邦法规的必要性3.生物药品中的专利权与法定专有权-我们真的需要两者吗？
5. Cost-effectiveness of adalimumab infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis [O] . Lauren Yokomizo, Berkeley Limketkai, K T Park 2016

机译：阿达木单抗英夫利昔单抗或维多珠单抗作为中度至重度溃疡性结肠炎的一线生物疗法的成本效益
6. 416a – Vedolizumab Shows Superior Efficacy Versus Adalimumab: Results of Varsity—The First Head-To-Head Study of Biologic Therapy for Moderate-To-Severe Ulcerative Colitis [O] . Bruce E. Sands, Laurent Peyrin-Biroulet, Edward V. Loftus, 2019

机译：416a - Vedolizumab显示出优异的功效与atabalimumab：varsity的结果 - 用于中度至重度溃疡性结肠炎的生物治疗的第一头脑研究
7. Catastrophic Versus Microscopic Damage: Applicability of Laboratory Measurements to Real Systems [R] . Foltyn, S. R., Jolin, L. J. 1984

机译：灾难性与微观损害：实验室测量对实际系统的适用性

P309 Are results from VARSITY applicable to real world? Adalimumab versus vedolizumab as first line biological in moderate-to-severe IBD

著录项

引文网络

相似文献

相关主题

期刊订阅